2020

Zhi-Yuan Lin, Li Liu, Yu Xia, Xiang Chen, Ying Xiong, Yang Qu, Jia-Jun Wang, Q. Bai, Jian-Ming Guo, Jiejie Xu

Oncoimmunology

DOI

2018

H. Xie, J. Zhang, Y. Zhu, Q. Fu, H.-L. Zhang, G. Shi, B. Dai, Jiejie Xu, D. Ye

DOI

2018

Tumor-infiltrating neutrophils predict therapeutic benefit of tyrosine kinase inhibitors in metastatic renal cell carcinoma

Jianru Wang, L. Liu, Chenzhang Ou, Jiejie Xu, Jianming Guo

European Urology Supplements

DOI

2017

Low CCL17 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma

Ying Xiong, Li Liu, Yu Xia, Jia-Jun Wang, W. Xi, Q. Bai, Yang Qu, Jiejie Xu, Jian-Ming Guo

BMC Cancer

DOI

2017

Prognostic value of copper transporter 1 expression in patients with clear cell renal cell carcinoma

Yu Xia, Li Liu, Q. Bai, Q. Long, Jia-Jun Wang, W. Xi, Jiejie Xu, Jian-Ming Guo

Oncology Letters

DOI

2017

Huyang Xie, Ze-Wei Wang, Q. Fu, Jiejie Xu, D. Ye

DOI

2017

Prognostic value of granulocyte colony-stimulating factor in patients with non-metastatic clear cell renal cell carcinoma

Zheng Liu, Yu Zhu, Yi-Wei Wang, Q. Fu, H. Fu, Ze-Wei Wang, Junyu Zhang, Gaoxiang Li, Jiejie Xu, B. Dai

OncoTarget

DOI

2017

HLA class I expression predicts prognosis and therapeutic benefits from tyrosine kinase inhibitors in metastatic renal-cell carcinoma patients

Jia-Jun Wang, Li Liu, Yang Qu, W. Xi, Yu Xia, Q. Bai, Ying Xiong, Q. Long, Jiejie Xu, Jian-Ming Guo

Cancer Immunology and Immunotherapy

DOI

2017

High expression of FUT3 is linked to poor prognosis in clear cell renal cell carcinoma

L. Meng, Le Xu, Yuanfeng Yang, Lin Zhou, Yuan Chang, Tian-Ming Shi, Cheng Tan, Hui-Min An, Yu Zhu, Jiejie Xu

OncoTarget

DOI

2017

High expression of CXC chemokine receptor 6 associates with poor prognosis in patients with clear cell renal cell carcinoma.

Yuan Chang, Lin Zhou, Le Xu, Q. Fu, Yuanfeng Yang, Zong-Ming Lin, Jiejie Xu

Urologic oncology

DOI

2017

Wei-Si Liu, Yidong Liu, Q. Fu, Wei-Juan Zhang, Le Xu, Yuan Chang, Jiejie Xu

American Journal of Cancer Research

2016

Increased expression of interleukin-8 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma

Hui-Min An, Yu Zhu, Huyang Xie, Yidong Liu, Wei-Si Liu, Q. Fu, D. Ye, Jiejie Xu

Tumor Biology

DOI

2016

Chao Lin, Hao Liu, Zhen-Bin Shen, Heng Zhang, Hongyong He, He Li, Jing Qin, Xinyu Qin, Jiejie Xu, Yi-Hong Sun

2016

Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma

W-Q Wang, L. Liu, H-X Xu, C-T Wu, J-F Xiang, Jiejie Xu, C. Liu, J Long, Q-X Ni, Xianjun Yu

British journal of surgery

DOI

2016

Yuan Chang, Le Xu, Hui-Min An, Q. Fu, Lian Chen, Zong-Ming Lin, Jiejie Xu

International Journal of Clinical and Experimental Pathology

2015

Qi Bai, Li Liu, Qilai Long, Yu Xia, Jiajun Wang, Jiejie Xu, Jianming Guo

PubMed

2015

Haiou Liu, Jiejie Xu, Lei Zhou, Xiao-jing Yun, Lin Chen, Shan-Shan Wang, Lin-lin Sun, Yu-Mei Wen, Jian-Xin Gu

Cancer Research

DOI

Yuanyan Wei, Dan Liu, Yuqing Ge, Feng-Biao Zhou, Jiejie Xu, Hong Chen, Xiao-jing Yun, Jian-xin Gu, Jian-Hai Jiang

Cancer Letters

DOI

Ribosomal Rack1 Promotes Chemoresistance and Growth in Human Hepatocellular Carcinoma Coordinated Translation Initiation Is Coupled with Cell Cycle Progression and Cell Growth, Whereas Excessive Ribo- Some Biogenesis and Translation Initiation Often Lead to Tumor Transformation and Survival. Hepatoc

Yuan-Yuan Ruan, Lin-lin Sun, Yuqing Hao, Lijing Wang, Jiejie Xu, Wen Zhang, Jianhui Xie, Liang Guo, Lei Zhou, Xiao-jing Yun, Hongguang Zhu, Ai-Guo Shen, Jian-Xin Gu

精选作品

期刊论文

TP53 mutation-biased CD8+ T cell exhaustion drives lethal outcome and therapy resistance in urothelial carcinoma

FN1+ macrophages fuel aggressive sarcomatoid differentiation and immunotherapy refractory outcome in clear cell renal cell carcinoma

Lethal clinical outcome and immuno-fibrotic contexture in refractory urothelial carcinoma harboring MYC amplification and overexpression

Aberrant p53 fuels macrophage immunoregulatory polarization and refractory clinical outcome in urothelial carcinoma

Lethal clinical outcome and immune desert contexture in refractory gastric cancer harboring CCNE1 amplification and overexpression

Poor clinical outcomes and immunoevasive contexture in gastric cancer patients bearing p16 high phenotype

Lactate-Driven IL8+ Tumor-Associated Macrophages Mediate Immunosuppression and Resistance to Immunotherapy in Clear-Cell Renal Cell Carcinoma

SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

Clinical outcomes and immune contexture in SMARCA4 ‐deficient gastric cancer patients

ARID1A Loss plus CD8+ T-Cell Infiltration Associate with Favorable Clinical Outcomes in Urothelial Carcinoma

Smad4 loss identifies aggressive subtype with immunotherapy and anti-HER-2 treatment resistance in gastric cancer

TERT promoter mutations or protein overexpression define an aggressive subset with favourable immunotherapeutic response in advanced urothelial carcinoma

Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression

晚期肾癌系统治疗的不良反应

NKG2A+CD8+ T cells infiltration determines immunosuppressive contexture and inferior response to immunotherapy in clear cell renal cell carcinoma

Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer

VHL missense mutation delineate aggressive clear cell renal cell carcinoma subtype with favorable immunotherapeutic response

Impact of clonal TP53 mutations with loss of heterozygosity on adjuvant chemotherapy and immunotherapy in gastric cancer

Blockade of V‐domain immunoglobulin suppressor of T‐cell activation reprograms tumour‐associated macrophages and improves efficacy of PD‐1 inhibitor in gastric cancer

Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma

GRP/GRPR enhances alcohol-associated liver injury through the IRF1-mediated Caspase-1 inflammasome and NOX2-dependent ROS pathway

C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer

Integrating angiogenesis signature and tumor mutation burden for improved patient stratification in immune checkpoint blockade therapy for muscle-invasive bladder cancer.

Complement receptor C5aR1 blockade reprograms tumor‐associated macrophages and synergizes with anti‐PD‐1 therapy in gastric cancer

Clinical outcome and molecular landscape of patients with ARID1A‐loss gastric cancer

Targeting myeloid checkpoint Siglec-10 reactivates antitumor immunity and improves anti-programmed cell death 1 efficacy in gastric cancer

Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene KDM6A mutation

Erratum to “Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion” [Eur. Urol. 75(5) (2019) 752–763]

Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer

B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Intratumoral PD-1+CD8+ T cells associate poor clinical outcomes and adjuvant chemotherapeutic benefit in gastric cancer

ASO Visual Abstract: Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients

Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients.

Stromal Tumor-Associated Macrophage Infiltration Predicts Poor Clinical Outcomes in Muscle-Invasive Bladder Cancer Patients

TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer

Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer

Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer

CD103+CD8+ tissue-resident memory T cell infiltration predicts clinical outcome and adjuvant therapeutic benefit in muscle-invasive bladder cancer

Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer.

Poor clinical outcomes and immunoevasive contexture in SIRPα+ tumor-associated macrophages enriched muscle-invasive bladder cancer patients.

ASO Author Reflections: Optimization of Tumor Therapy for the Specific Immune Microenvironment of Gastric Cancer

Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis

Clinical Outcomes and Immune Metrics in Intratumoral Basophil-Enriched Gastric Cancer Patients

Poor clinical outcomes and immunoevasive contexture in CXCL13+CD8+ T cells enriched gastric cancer patients

Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer

Immune inactivation by APOBEC3B enrichment predicts response to chemotherapy and survival in gastric cancer

Author Correction: EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma

Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma

Intratumoral CXCL13+CD8+T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma

Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer

TIM3+ cells in gastric cancer: clinical correlates and association with immune context

Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients

Intratumoral CCR5+ neutrophils identify immunogenic subtype muscle-invasive bladder cancer with favorable prognosis and therapeutic responses

MP18-04 TUMOR-INFILTRATING TNFRSF9+ CD8 T CELLS IN RENAL CELL CARCINOMA HOLD BOTH EXHAUSTION AND EFFECTOR PHENOTYPE AND RESPONSE BETTER TO IMMUNOTHERAPY

MP18-03 TUMOR-INFILTRATING CD39+CD8+ T CELLS DETERMINE POOR PROGNOSIS AND IMMUNE EVASION IN CLEAR-CELL RENAL CELL CARCINOMA PATIENTS

CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer

Poor clinical outcomes of intratumoral dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin-positive macrophages associated with immune evasion in gastric cancer.

Tumor-infiltrating podoplanin+ cells in gastric cancer: clinical outcomes and association with immune contexture

CCR5 blockade inflames antitumor immunity in BAP1-mutant clear cell renal cell carcinoma

Poliovirus receptor CD155 is up-regulated in muscle-invasive bladder cancer and predicts poor prognosis.

Poor clinical outcomes and immunoevasive contexture in interleukin‐9 abundant muscle‐invasive bladder cancer

Stromal LAG-3+ cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture

Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8+ T cells in gastric cancer

Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin+ cell abundance

Tumor-infiltrating IL-17A+ cells determine favorable prognosis and adjuvant chemotherapeutic response in muscle-invasive bladder cancer

Latency-associated Peptide Identifies Immunoevasive Subtype Gastric Cancer With Poor Prognosis and Inferior Chemotherapeutic Responsiveness

Tumor-infiltrating TNFRSF9+ CD8+ T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response

Blockade of DC-SIGN+ Tumor-Associated Macrophages Reactivates Antitumor Immunity and Improves Immunotherapy in Muscle-Invasive Bladder Cancer

Intratumoral IL22‐producing cells define immunoevasive subtype muscle‐invasive bladder cancer with poor prognosis and superior nivolumab responses

Lymphocyte‐activation gene 3 expression associates with poor prognosis and immunoevasive contexture in Epstein‐Barr virus‐positive and MLH1‐defective gastric cancer patients

Identification and validation of an immunogenic subtype of gastric cancer with abundant intratumoural CD103+CD8+ T cells conferring favourable prognosis

Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients

Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.

Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response

PAK1 expression determines poor prognosis and immune evasion in metastatic renal cell carcinoma patients.

Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer

MP21-02 TUMOR ASSOCIATED NEUTROPHILS SUPPRESS CD8+ T CELLS RESPONSIVENESS TO DETERIORATE SURVIVAL IN HUMAN RENAL CANCER